Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 14, 2009Therapeutic Advances in Cardiovascular DiseaseOpen Access

Studies such as the MOSES trial suggest ARBs may offer additional, blood pressure-independent protection against stroke and cardiovascular events compared to other antihypertensive agents.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Do angiotensin receptor blockers offer superior protection against stroke compared to other antihypertensive agents in hypertensive patients?

Population

Hypertensive patients and patients with a previous stroke

Comparison

Angiotensin receptor blockers (ARBs) vs Other antihypertensive agents (e.g., nitrendipine)

Design

Review

Authors

PAPedro ArmarioASAlejandro de la Sierra

Discussion

Loading...

Member takes

Overview

May support ARB preference for stroke prevention beyond BP control; leaves open class superiority pending confirmatory trials.

Structured PICO

Do angiotensin receptor blockers offer superior protection against stroke compared to other antihypertensive agents in hypertensive patients?

P
Population
Hypertensive patients and patients with a previous stroke
I
Intervention
Angiotensin receptor blockers (ARBs)
C
Comparator
Other antihypertensive agents (e.g., nitrendipine)
O
Outcome
Stroke prevention (primary and secondary)hard clinical

Angiotensin receptor blockers may provide blood pressure-independent neuroprotective effects, offering superior stroke prevention compared to other antihypertensive classes.

Cite This Study

Armario et al. (2009) studied this question.

synapsesocial.com/papers/6a7cc9aba42cae215d7cd8d3https://doi.org/10.1177/1753944709104164
View Full Paper
Ask AI
Bookmark
Share